Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ulipristal acetate
- Development stage
- Approved
- Lead developer
- MetiMedi Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
OMT-110 is a repositioned small molecule drug candidate consisting of a subcutaneous formulation of **ulipristal acetate**, a selective progesterone receptor modulator (SPRM). Developed by the South Korean biotechnology company **OncoMylo**, OMT-110 is being investigated for the treatment of refractory metastatic colorectal cancer (mCRC). While ulipristal acetate is traditionally approved for emergency contraception and the treatment of uterine fibroids, its repositioning for oncology is based on potential immunomodulatory effects and its ability to influence the tumor microenvironment. A Phase I dose-escalation study (KCT0005336) evaluated OMT-110 in patients with advanced mCRC who had failed standard therapies, demonstrating safety and tolerability at doses up to 100 mg daily administered in a 21-day on/7-day off cycle. The drug is hypothesized to inhibit tumor progression by modulating progesterone-mediated signaling and enhancing anti-tumor immune responses.
- Brand names
- EllaEsmyaFibristalEllaOne
- Other names
- ulipristalulipristal acetate subcutaneous
02
Targets
PR (Progesterone receptor)
Beyond the preview
Go deeper on ulipristal acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ulipristal acetate.